Procainamide Hydrochloride

Selected form

Procainamide Hydrochloride

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Procainamide Hydrochloride

Quick Facts

Property	Description
Active Ingredient	Procainamide
Pharmacological Class	Class 1A Antiarrhythmic Agent
Primary Form	Sterile Injection Solution (IV/IM)
General Purpose	Heartbeat Rhythm Regulation
Origin/Type	Synthetic Chemical (Amide Derivative)

What Type of Medicine is Procainamide Hydrochloride?

Procainamide Hydrochloride is a specific synthetic chemical entity classified as a Class 1A antiarrhythmic agent. It belongs to the specialized group of medications used to correct the heart’s electrical rhythm. This compound is the stable hydrochloride salt of the active compound, Procainamide, and is considered a single-ingredient product.

Chemically, it is defined as an amide derivative and an analog of the local anesthetic procaine. Its classification under the Vaughan-Williams system defines its crucial role as a targeted drug for stabilizing serious cardiac rhythm disorders, a use which is clinically recognized across major medical guidelines.

What is the General Purpose of This Antiarrhythmic Agent?

The general purpose of Procainamide Hydrochloride is Heartbeat Rhythm Regulation. The medication is fundamentally designed to help the heart achieve a more stable and coordinated electrical rhythm by functioning as a sodium channel blocker. This action involves controlling the speed of electrical signals within the heart muscle, helping to slow down and stabilize the rapid or disorganized activity that characterizes an arrhythmia.

For example, it is typically used in a clinical setting to terminate certain acute ventricular arrhythmias, acting to suppress abnormal excitability in the heart muscle. This means the medicine is effective at making the heart cells less likely to generate dangerous, abnormal electrical impulses.

Composition and Available Form

Procainamide Hydrochloride is predominantly supplied as a sterile injection solution dissolved in an aqueous vehicle (water for injection) for use in highly controlled medical environments. The availability of the medicine primarily as an injection solution underscores its specialized role in acute care, where rapid intravenous (IV) or intramuscular (IM) delivery is essential. While Pronestyl was a prominent brand name for the oral form, the injectable solution is the standard format used today, reflecting the drug's current clinical positioning for acute intervention rather than routine maintenance.

Regulatory References

What side effects are possible with Procainamide Hydrochloride?

Possible Side Effects and Safety Information

Procainamide Hydrochloride carries a Boxed Warning regarding the potential for serious, and sometimes fatal, blood disorders including agranulocytosis, neutropenia, and bone marrow depression. Due to these risks, its use is generally reserved for treating life-threatening ventricular arrhythmias.

Key Adverse Reactions

Immunological: Prolonged use is strongly associated with the development of a Lupus erythematosus-like syndrome, which may include symptoms such as joint pain, fever, chills, pleurisy, and pericarditis. The development of a positive anti-nuclear antibody (ANA) test is common.
Cardiovascular: Acute, serious cardiotoxicity can occur, including hypotension (especially with rapid intravenous infusion), new or worsened arrhythmias (proarrhythmia), and serious conduction disturbances like ventricular asystole or fibrillation. Changes on the ECG, such as QRS, QTc, and PR prolongation, require careful monitoring.
Gastrointestinal and Nervous System: Common effects include anorexia, nausea, vomiting, diarrhea, dizziness, and mental depression.

Safety Considerations

Classification	Detail
Restrictions	Contraindicated in patients with established systemic lupus erythematosus, second- or third-degree atrioventricular (AV) block (unless paced), or torsades de pointes.
Monitoring	Complete blood counts (CBCs) are mandatory, particularly during the first 12 weeks of therapy, and must be performed immediately if signs of infection, bleeding, or bruising appear. Serial ECGs are required to monitor for cardiotoxicity.
Special Populations	Patients with kidney or liver impairment may require dose adjustment due to slower drug elimination, increasing the risk of high plasma levels and toxicity.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes overdose of Procainamide Hydrochloride as a severe medical event primarily impacting the cardiac and central nervous systems (CNS).

Documented Overdose Manifestations

Symptoms and signs of overdose include progressive widening of the QRS complex, prolonged P-R and Q-T intervals, and increasing A-V block on the ECG, which may lead to life-threatening Ventricular Tachycardia or Fibrillation. Systemic manifestations include severe hypotension, tremor, central nervous depression, and respiratory depression.

When to Seek Urgent Medical Help

Regulatory documents mandate seeking immediate medical attention for suspected overdose. Specifically, emergency services (911) must be contacted immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Management Notes

Official labeling states that no specific antidote for Procainamide is known. Management is symptomatic and supportive. Procedures described include continuous monitoring of vital signs, the use of intravenous pressor agents for hypotension, and the potential use of hemodialysis to remove the drug and its metabolite. Patients with impaired kidney or liver function are noted to be at increased risk for toxicity due to drug accumulation.

Therapeutic Uses of Procainamide Hydrochloride

Procainamide Hydrochloride: Main Uses and Benefits

Procainamide Hydrochloride is a therapeutic option used to help manage various disturbances in the heart's rhythm. The primary benefit of this treatment is its capacity to help support a more stable and regular heart rate when the electrical activity becomes fast or irregular.

The medication is considered for managing clinically significant conditions, including certain types of premature ventricular contractions (PVCs) and ventricular tachycardia. It may also be utilized in the management of select supraventricular arrhythmias. These rhythm disorders often lead to symptoms such as palpitations and feelings of dizziness. By addressing these abnormal beats, Procainamide Hydrochloride can help reduce the frequency and severity of these distressing symptoms.

Quick Fact: Relief for Irregular Heart Rhythms

Regulatory References

NIH DailyMed drug information

Eligibility and Restrictions for Use

Procainamide Hydrochloride is restricted to use in patients where the benefit of treatment clearly outweighs the risks, as it can be associated with serious adverse effects. Eligibility is formally contraindicated for several specific populations:

Patients with Complete Heart Block (due to the risk of asystole).
Patients with an established diagnosis of Systemic Lupus Erythematosus (SLE), as the drug is highly likely to aggravate symptoms.
Individuals with known Idiosyncratic Hypersensitivity (e.g., acute allergic dermatitis, asthma) to procainamide.
Patients experiencing Torsades de Pointes ventricular arrhythmia, which the drug may worsen.

Restrictions and Special Considerations

Pediatric Use: Safety and effectiveness have not been established in pediatric patients.
Elderly Patients: Dosage adjustment is often required due to age-related changes in kidney function, which can slow the drug's elimination.
Impaired Organ Function: Caution is required, and doses must be modified for individuals with renal impairment or hepatic impairment to prevent drug accumulation and toxicity.
Pregnancy/Lactation: Use in pregnancy (Category C) should only occur if clearly needed. Because the drug and its metabolite pass into breast milk, the manufacturer recommends the decision to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

The official regulatory profile for Procainamide Hydrochloride defines its interaction structure primarily through two domains: pharmacodynamic synergism and pharmacokinetic clearance inhibition. This structure mandates strict administration constraints to prevent altered drug exposure or enhanced cardiac effects.

The highest severity classification is Contraindicated, applying to co-administration with specific other antiarrhythmic agents like Dofetilide and agents such as Fingolimod. This restriction is due to the documented risk of additive electrophysiological effects, specifically QTc interval prolongation and enhanced arrhythmogenic activity.

Exposure-Altering Agents: Co-administration with agents that interfere with renal tubular secretion, such as Cimetidine, results in a clinically significant increase in the plasma concentrations of Procainamide and its active metabolite, N-acetylprocainamide (NAPA). Amiodarone is also documented to increase exposure and prolong the half-life.
Metabolic Effects: Ethanol (Alcohol) intake is documented as potentially increasing the acetylation rate of Procainamide, which may alter the concentration of the parent drug.
Population Notes: The label notes that compromised renal function in all patients, including geriatric patients, reduces drug clearance, increasing the risk of accumulation from co-administered clearance inhibitors. No mandatory timing separation rules are specified in the regulatory labeling.

Mechanism of Action

Procainamide Hydrochloride functions as a Class IA antiarrhythmic agent, primarily modulating cardiac electrical activity by acting on myocardial membranes. Its primary biological target is the voltage-gated sodium channel ( Na^+ channel) in the heart. Procainamide binds to and obstructs these channels, which are responsible for the rapid influx of Na^+ ions during Phase 0 (depolarization) of the cardiac action potential. This inhibition reduces the maximum rate of depolarization (V max).

The molecular consequence is a slowing of impulse conduction velocity across the myocardium. Additionally, Procainamide inhibits potassium efflux during Phase 3 (repolarization). This blockade of K^+ current extends the action potential duration (APD) and increases the effective refractory period (ERP) in both atrial and ventricular tissue, modulating myocardial excitability. The overall effect is a prolonged action potential and refractory period, altering the intrinsic electrical cycling of the heart.

Dosage and Administration Information

How to Use Procainamide Hydrochloride

Procainamide Hydrochloride is administered exclusively by injection and is generally reserved for use in highly controlled medical settings. The application of this Class 1A antiarrhythmic agent is defined by specific procedural steps, rates, and dose limits.

Administration Guidelines

Instruction Area	Description
Route of Administration	Administered via Intravenous (IV) injection or continuous infusion, or as an Intramuscular (IM) injection.
Dosing Schedule	IV Loading: Fixed 100 mg doses are typically administered every 5 minutes at a rate not to exceed 50 mg/minute until a maximum total dose is reached. IV Maintenance: A continuous infusion is maintained within a therapeutic range of 1 to 6 mg per minute.
Preparation	The solution must be diluted prior to intravenous administration, commonly to 2 mg/mL or 4 mg/mL concentrations. Solutions with color darker than light amber must be discarded.
Special Conditions	Therapy initiation must occur in a hospital or emergency facility under close observation, including continuous ECG and blood pressure monitoring.
Population Adjustments	Dosing must be adjusted for patients with renal or hepatic impairment, often requiring a dose reduction of up to 50% to two-thirds of the standard regimen.

Procedural Use and Duration

The administration protocol defines a transition from rapid, intermittent use to continuous maintenance.

Step 1: Initial doses are administered at 5-minute intervals with a strict rate limit.
Step 2: Upon stabilization, the medicine is transitioned to a continuous IV infusion for maintenance.
Step 3: The IV treatment is intended for short-term acute control and should be discontinued and switched to an oral regimen once the patient's cardiac rhythm is stable.

This structured approach ensures the medicine is used within the narrow therapeutic window and follows established clinical procedures.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Procainamide Hydrochloride

Procainamide Hydrochloride was studied for its potential role in regulating certain heart rhythm disturbances. The available evidence base includes randomized controlled trials (RCTs), retrospective reviews, and smaller cohort studies, with the research largely examining temporary physiological imbalance during an acute episode.

Evidence for Acute Sustained Ventricular Tachycardia

Research was studied for its use in exploring temporary changes during sustained, stable ventricular tachycardia (VT) in adult populations. These studies primarily focused on episodes where symptoms become more noticeable, specifically VT. The main outcomes monitored were measurements of the time required for the heart to resume a baseline rhythm and the frequency of acute systemic or functional imbalance.

In a key randomized trial (PROCAMIO), the study findings described patterns observed where the immediate conversion endpoint was measured as achieved in a greater number of episodes with Procainamide compared to the comparator drug. The primary safety outcomes of the key acute VT trial monitored major adverse cardiac events, and studies monitored patterns where the rate was observed to be lower in the Procainamide group compared to the comparator.

Long-Term Outcomes and Follow-up Duration

Research describes patterns related to the drug's effects beyond the acute treatment phase. Researchers examined the long-term use of this class of antiarrhythmics in non-life-threatening settings, such as for the suppression of asymptomatic premature ventricular contractions (PVCs).

The research highlights a historical pattern where, despite measurements of suppression of the asymptomatic abnormal heartbeats, large trials involving similar drug classes contribute to the broader evidence landscape regarding long-term health outcomes.

What Remains Uncertain About Procainamide Hydrochloride Research

The evidence quality varies across studies, with the most focused data focusing primarily on short-term symptom changes. The follow-up durations were limited, typically only covering the first 24 hours. Long-term effects and the impact on health outcomes in non-acute settings are not well characterized by the current evidence base. Additionally, the data for certain groups remain insufficient, and regulatory bodies describe patterns where the research for settings like PVCs is limited regarding long-term health outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Procainamide Hydrochloride (FAQ)

Q: What is Procainamide Hydrochloride used for?

A: Procainamide Hydrochloride is an antiarrhythmic medicine used to treat specific, documented, life-threatening heart rhythm problems, known as ventricular arrhythmias (such as sustained ventricular tachycardia). It is typically reserved for use in carefully selected patients when the benefits are considered to outweigh the potential risks.

Q: How does Procainamide Hydrochloride work?

A: Procainamide Hydrochloride is a Class 1A antiarrhythmic agent. It works by affecting the electrical activity in the heart muscle. Specifically, it blocks fast sodium channels, which helps to slow the heart's conduction velocity and prolong the effective refractory period, ultimately reducing myocardial excitability and helping to stabilize the abnormal heart rhythm.

Q: Can Procainamide Hydrochloride cause new or worsened arrhythmias?

Yes, like many antiarrhythmic medicines, Procainamide Hydrochloride has proarrhythmic effects, meaning it can potentially worsen existing arrhythmias or cause new ones.
This risk is a reason why its use is generally reserved for more severe, life-threatening arrhythmias, and it's not recommended for less severe or asymptomatic heart rhythm issues.

Q: What is the risk of a lupus-like syndrome with Procainamide Hydrochloride?

A: Prolonged use of Procainamide Hydrochloride is associated with a high rate of developing positive antinuclear antibody (ANA) titers, and it can lead to a condition known as a drug-induced lupus erythematosus-like syndrome.

Symptoms of this syndrome can include fever, muscle pain, and joint pain.
Your healthcare provider will monitor you for signs of this condition.

Q: What kind of monitoring is required when taking Procainamide Hydrochloride?

A: Due to the serious potential side effects, therapy with Procainamide Hydrochloride requires close medical supervision and monitoring, typically initiated in a hospital setting.

Continuous Electrocardiogram (ECG) monitoring is essential to track heart rhythm, particularly watching for widening of the QRS complex and prolongation of the QT interval, which can be signs of toxicity.
Blood pressure should be monitored frequently.
Blood tests are required to check complete blood counts (CBCs), including white blood cell and platelet counts, especially during the first three months of therapy, and also to monitor the levels of Procainamide and its active metabolite in the blood.

How should Procainamide Hydrochloride be stored and disposed of?

Storage and Disposal Instructions for Procainamide Hydrochloride

Procainamide Hydrochloride Injection must be stored at Controlled Room Temperature, which is defined by regulatory standards as a range between 20 C and 25 C (68 F to 77 F). The medication must be kept out of the sight and reach of children.

Stability and Handling

Condition	Regulatory Requirement
Temperature	Store between 20 C and 25 C.
Visual Inspection	Mandatory check for particulate matter or discoloration before use.
Discoloration Rule	The solution must be discarded if it is observed to be darker than light amber.